Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan 30:7:e46580.
doi: 10.2196/46580.

From the Cochrane Library: Systemic Interventions for Steven-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS/TEN Overlap Syndrome

Gaurav Nitin Pathak  1 , Thu Minh Truong  1   2 , Amit Singal  2 , Viktoria Taranto  3 , Babar K Rao  1   4 , Audrey A Jacobsen #  5   6   7
Affiliations
Comment

From the Cochrane Library: Systemic Interventions for Steven-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS/TEN Overlap Syndrome

Gaurav Nitin Pathak et al. JMIR Dermatol. .
No abstract available

Keywords: IVIG; SJS; Steven-Johnson syndrome; TEN; corticoid; corticosteroid; corticosteroids; dermatological; dermatology; etanercept; fatal; intravenous immunoglobulin; life-threatening; necrolysis; prednisolone; skin; steroid; steroids; systematic; toxic epidermal necrolysis; treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: BR is a speaker for Incyte and Amgen. AAJ has received the Cochrane Scholarship for the original Cochrane review from the American Academy of Dermatology. All other authors have no conflicts of interest to declare.

Comment on

References

    1. Jacobsen A, Olabi B, Langley A, Beecker J, Mutter E, Shelley A, Worley B, Ramsay T, Saavedra A, Parker R, Stewart F, Pardo JP. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013130. doi: 10.1002/14651858.CD013130.pub2. https://europepmc.org/abstract/MED/35274741 - DOI - PMC - PubMed
    1. Azfar NA, Zia MA, Malik LM, Khan AR, Jahangir M. Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Pakistan Association of Dermatologists. 2010;20(3):158–162. http://www.jpad.com.pk/index.php/jpad/article/view/410/385
    1. González-Herrada C, Rodríguez-Martín S, Cachafeiro L, Lerma V, González O, Lorente JA, Rodríguez-Miguel A, González-Ramos J, Roustan G, Ramírez E, Bellón T, de Abajo FJ, PIELenRed Therapeutic Management Working Group Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol. 2017 Oct;137(10):2092–2100. doi: 10.1016/j.jid.2017.05.022. https://linkinghub.elsevier.com/retrieve/pii/S0022-202X(17)31645-7 S0022-202X(17)31645-7 - DOI - PubMed
    1. Han F, Zhang J, Guo Q, Feng Y, Gao Y, Guo L, Hou Y, An J, Wang X, Yan B, Zheng Y, Song J, Li M, Wang G. Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. J Crit Care. 2017 Dec;42:65–68. doi: 10.1016/j.jcrc.2017.07.002.S0883-9441(17)30434-3 - DOI - PubMed
    1. Jagadeesan S, Sobhanakumari K, Sadanandan SM, Ravindran S, Divakaran MV, Skaria L, Kurien G. Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian J Dermatol Venereol Leprol. 2013;79(4):506–511. doi: 10.4103/0378-6323.113080. doi: 10.4103/0378-6323.113080.ijdvl_2013_79_4_506_113080 - DOI - DOI - PubMed

LinkOut - more resources